THALES/TELIT-CINTERION
27.2.2024 09:01:30 CET | Business Wire | Press release
Telit Cinterion IoT modules featuring Thales Instant Connect can be remotely activated for cellular connectivity at the time of device installation or during in-field operation. This streamlines IoT deployments as it simplifies supply chain, device installation and maintenance, helping to keep IoT devices connected anywhere, and at all times. Aidon, a leader in smart metering solutions, is the first to benefit from this partnership and solution, deploying IoT modules and initial connectivity from a single vendor, Telit Cinterion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240227054738/en/
credit > sergray
By integrating Thales technology into Telit Cinterion modules, enterprises can enjoy instant out-of-the-box connectivity activation irrespective of the grid of available mobile networks. The collaboration between the two companies on this innovative solution enables them to get their IoT connected products in the market quickly, allowing them to reap the benefits of digital transformation that is at the core of the IoT promise.
The way the solution works is that, at the end of device production or when it is deployed in the field, the Telit Cinterion module uses the initial connectivity provided by Thales Instant Connect, to download the target local connectivity from the network operators selected by the IoT service provider. This allows device manufacturers and service providers to postpone selecting a connectivity provider until after the device is manufactured and throughout the deployment process. It can also be used during in-field operation, enabling deployed devices to stay connected throughout unexpected cellular network outages. This flexibility is particularly beneficial in situations where the devices are deployed across different regions or countries, as it allows for seamless integration with local network operators.
“Helping our enterprise customers to quickly launch and monetize IoT is our mission at Telit Cinterion. Adding the Thales eSIM to our modules in combination with our SIM provisioning and global MVNO services to streamline the final connectivity provider selection is a game changer in the industry. This powerful solution delivers unparalleled adaptability to changing circumstances and simplifies supply chain and logistics because it is based on a single eSIM with Thales Instant Connect, which can be shipped anywhere in the world,” said Manish Watwani, Chief Marketing and Product Officer at Telit Cinterion.
“The IoT eSIM solution is an important innovation, ensuring production flexibility and connectivity of our smart meters, even in rural areas, and all without the need for physical handling of SIMs. The solution provides a true operator selection and provisioning at any stage of the product lifetime. It is improving our ability to get smart meters connected, stay connected and adapt to new metering as-a-service business models,” said Petri Ounila, Director, IoT Devices, Aidon.
“Thales aims to support IoT adopters and streamline device deployment with our eSIM with initial connectivity via Thales Instant Connect service. This simplifies and accelerates large scale IoT deployments for device makers, benefiting all stakeholders in the value chain. Thales is pleased to work with Telit Cinterion to support its success in cellular connectivity and speed up device deployment,” said Guillaume Lafaix, Senior Vice President Mobile Connectivity Solutions at Thales.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfill their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 77,0001 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.
_______________________________
1 Excluding Transport business, which is being divested
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227054738/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
